This rings a faint bell of the Clinton's involvement in profiting from tainted blood. It is another good piece of research that will result in naught.


Clinton Foundation distributed useless drugs to AIDS patients
Pharmaceutical executive: 'It's just blacks dying'
04.26.2015
Jerome R. Corsi About | Email | Archive

NEW YORK – While skimming tens of millions of dollars from U.N. levies imposed on airline travelers, the Clinton Foundation’s Clinton Health Aids Initiative worked closely with a pharmaceutical company in India to distribute “drastically substandard” generic antiretroviral drugs to Third World countries that had no chance of helping HIV/AIDs patients, according to a Wall Street analyst.

As WND reported Wednesday, over the past six weeks, Charles Ortel shared with WND, prior to publication, the results of his six-month, in-depth investigation into what he characterizes as an elaborate scheme devised by the Clintons to enrich themselves. WND reported Thursday the Clintons appear to have personally profited from an airline-ticket levy program run by the U.N. group UNITAID that used the Clintons’ international prestige to “leverage” manufacturers of prescription quality drugs and health-care products and sell them to developing countries at a discount price.

Ira Magaziner, the chief executive officer and vice chairman of the Clinton Health Aids Initiative, known as CHAI, approached the Indian company, Ranbaxy, in 2002 to negotiate a deal. It allowed CHAI to assume a controlling position to administer the airline-ticket levy program through UNITAID, a program of the U.N.’s World Health Organization in Geneva.

CHAI proposed to Ranbaxy that “they could put the developing countries together to form a sort of ‘buying club’ that could “ramp up economies of scale and lower cost,” according to Professors Ethan B. Kapstein of Arizona State University and Joshua W. Busby of the University of Texas at Austin in their Cambridge University Press 2013 book “AIDS Drugs for All.”

...........................................

Clinton hooks up with UNITAID and WHO

According to the UNITAID website, CHAI, established by President Bill Clinton in 2002, approached UNITAID, created in 2006, “to reach groups in developing countries that were neglected by HIV drug markets,” resolving to combine forces in 2008.

The UNITAID-CHAI joint venture’s goal was to combine UNITAID’s innovative financing that relied on levies charged on airline tickets in participating countries with CHAI’s entrepreneurial approach to getting international pharmaceutical companies to produce antiretroviral, or ARV, drugs throughout the developed world at prices discounted because of the massive scale of the market.

“The deal positioned the Clinton Foundation to have access to hundreds of millions of dollars from what amounted to a tax imposed on millions of average airline passengers,” explained Ortel.

“The Clinton Foundation financial reporting strongly suggests the Clintons were able to skim off for their personal use tens of millions of dollars from the funds WHO sent to CHAI from UNITAID levies,” Ortel said.

........................................

Ranbaxy on May 13, 2013, pleaded guilty to seven federal criminal counts of selling adulterated drugs with an intent to defraud.

The company failed to report that its drugs didn’t meet specifications and made intentionally false statements to the government.

Ranbaxy agreed to pay $500 million in fines, forfeitures and penalties, the most ever levied against a generic-drug company.

A Fortune magazine article in May 2013 by investigative reporter Katherine Eban titled “Dirty Medicine” detailed the Ranbaxy pharmaceutical scandal.

The article captured the moral bankruptcy of Ranbaxy through a conference call Dr. Kathy Spreen, Ranbaxy’s executive director of clinical medicine, had with a dozen company executives in which a participating Ranbaxy executives dismissed concern that the company was producing defective drugs.

“Who cares? It’s just blacks dying,” the executive said, according to Fortune.

........................................

Fortune reported Ranbaxy “manipulated almost every aspect of its manufacturing process to quickly produce impressive-looking data,” including forging standard operating procedures to hide from health inspectors the truth that Ranbaxy never stopped substituting “cheaper, lower-quality ingredients in place of better ingredients, to manipulate test parameters to accommodate higher impurities, and even to substitute brand-name drugs in lieu of their own generics in bioequivalence tests to produce better results.”

...................................................

More:
Read more at http://www.wnd.com/2015/04/clinton-found...bFGeGjDwmZXU.99